Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NRG1 siRNA
- Development stage
- Preclinical
- Lead developer
- Thomas Jefferson University
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
NRG1 siRNA is a small interfering RNA (siRNA) designed to silence the expression of the neuregulin-1 (NRG1) gene through RNA interference. NRG1 is a growth factor and a ligand for the ErbB3 (HER3) receptor; its binding induces ErbB3/ErbB2 heterodimerization and activates downstream survival pathways, including the PI3K/AKT signaling cascade. In preclinical research, particularly in cutaneous melanoma models that are wild-type for BRAF and NRAS, NRG1 siRNA has been utilized to demonstrate that autocrine NRG1 production drives tumor cell viability. By knocking down NRG1 expression, the siRNA reduces ErbB3 and AKT phosphorylation, thereby inhibiting tumor cell growth and survival. This approach highlights the NRG1-ErbB3-ErbB2 axis as a potential therapeutic target in specific cancer subsets.
- Other names
- neuregulin-1 siRNAneuregulin1 siRNAneuregulin 1 siRNAsiRNA targeting NRG1NRG1 small interfering RNANRG-1 small interfering RNANRG 1 small interfering RNA
02
Targets
Neuregulin 1 mRNAInnate immune RNA sensors
Beyond the preview
Go deeper on NRG1 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NRG1 siRNA.